Sotyktu™ (deucravacitinib) has been approved for use as an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to severe plaque psoriasis in adults.

• Manufactured by Bristol-Myers Squibb, Sotyktu is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.
• Sotyktu is not recommended for use in combination with other potent It is currently available at wholesale acquisition cost (WAC) of $6,164.78 for a 30-day supply.